Search results: Sage Journals

Restricted accessResearch articleFirst published February, 2011

Qualitative Spectral OCT/SLO Analysis of Drusen Change in Dry Age-Related Macular Degeneration Patients Treated with Copaxone

Gennady Landa, Richard B. Rosen, Amar Patel [...]

Journal of Ocular Pharmacology and Therapeutics

Restricted accessResearch articleFirst published June, 1996

Management of relapsing/remitting multiple sclerosis with copolymer I (Copaxone)

Kenneth P Johnson

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published January, 2007

Human Mesenchymal Stem Cells Constitutively Express Chemokines and Chemokine Receptors That Can Be Upregulated by Cytokines,IFN-β,and Copaxone

Juliana Croitoru-Lamoury, Francois M.J. Lamoury, John J. Zaunders [...]

Journal of Interferon & Cytokine Research

Free accessResearch articleFirst published January, 2012

Comparative Long-Term Preclinical Safety Evaluation of Two Glatiramoid Compounds (Glatiramer Acetate,Copaxone®,and TV-5010,Protiramer) in Rats and Monkeys

Yuval Ramot, Moti Rosenstock, Ety Klinger [...]

Toxicologic Pathology

Restricted accessResearch articleFirst published January, 2004

Management of Glatiramer (Copaxone) Reactions: Experience with Desensitization

SR Inamdar, M Rensel, F Hsieh [...]

Journal of Investigative Medicine

Restricted accessResearch articleFirst published July, 2008

Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone®)

C Iarlori, D Gambi, A Lugaresi [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2016

Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis

Michael D Ludwig, Anthony P Turel, Ian S Zagon [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Restricted accessResearch articleFirst published December, 2001

A prospective,open-label treatment trial to compare the effect of IFNβ-1a (Avonex®),IFNβ-1b (Betaseron®),and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy

Omar A Khan, Alexandros C Tselis, John A Kamholz [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published December, 2003

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

K P Johnson, B R Brooks, C C Ford [...]

Multiple Sclerosis Journal

Restricted accessCase reportFirst published February, 2019

In Re: Copaxone Consol. Cases United States Court of Appeals of the Federal Circuit,2018 906 F.3d 1013

Biotechnology Law Report

Restricted accessResearch articleFirst published February, 2011

Qualitative Spectral OCT/SLO Analysis of Drusen Change in Dry Age-Related Macular Degeneration Patients Treated with Copaxone

Gennady Landa, Richard B. Rosen, Amar Patel [...]

Journal of Ocular Pharmacology and Therapeutics

Restricted accessResearch articleFirst published June, 1996

Management of relapsing/remitting multiple sclerosis with copolymer I (Copaxone)

Kenneth P Johnson

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published January, 2007

Human Mesenchymal Stem Cells Constitutively Express Chemokines and Chemokine Receptors That Can Be Upregulated by Cytokines,IFN-β,and Copaxone

Juliana Croitoru-Lamoury, Francois M.J. Lamoury, John J. Zaunders [...]

Journal of Interferon & Cytokine Research

Free accessResearch articleFirst published January, 2012

Comparative Long-Term Preclinical Safety Evaluation of Two Glatiramoid Compounds (Glatiramer Acetate,Copaxone®,and TV-5010,Protiramer) in Rats and Monkeys

Yuval Ramot, Moti Rosenstock, Ety Klinger [...]

Toxicologic Pathology

Restricted accessResearch articleFirst published January, 2004

Management of Glatiramer (Copaxone) Reactions: Experience with Desensitization

SR Inamdar, M Rensel, F Hsieh [...]

Journal of Investigative Medicine

Restricted accessResearch articleFirst published July, 2008

Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone®)

C Iarlori, D Gambi, A Lugaresi [...]

Multiple Sclerosis Journal

Open accessResearch articleFirst published 2016

Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis

Michael D Ludwig, Anthony P Turel, Ian S Zagon [...]

Multiple Sclerosis Journal – Experimental,Translational and Clinical

Restricted accessResearch articleFirst published December, 2001

A prospective,open-label treatment trial to compare the effect of IFNβ-1a (Avonex®),IFNβ-1b (Betaseron®),and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy

Omar A Khan, Alexandros C Tselis, John A Kamholz [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published December, 2003

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

K P Johnson, B R Brooks, C C Ford [...]

Multiple Sclerosis Journal

Restricted accessCase reportFirst published February, 2019

In Re: Copaxone Consol. Cases United States Court of Appeals of the Federal Circuit,2018 906 F.3d 1013

Biotechnology Law Report